What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2026-03-13 compared with 2025-03-13 · 157 added, 144 removed, 90 unchanged (77% of the section changed)

We have developed and are commercializing products for managing animal pest populations through fertility control.

We have developed and are commercializing products for managing animal pest populations through fertility control and population management strategies.

Our current products focus on rat and mouse populations, and are known as:

ContraPest, Evolve Rat, and Evolve Mouse.

As far back as we can trace, rodents - and in particular rats - have been foes to mankind.

Rodents pose threats to human and animal health, food security and infrastructure around the world, and we have spent centuries trying to mitigate the problems associated with these pests.

Rodents are known to be reservoir hosts for at least 60 zoonotic diseases and the potential transmission of these diseases creates a global risk to public health and safety, as well as agriculture.

As far back as we can trace, rodents have been foes to mankind.

Today, they remain one of the most resilient and economically destructive vertebrate pests on the planet.

Rodents threaten human and animal health, food security, and infrastructure worldwide, and humanity has spent centuries attempting to mitigate the problems associated with their proliferation.

Rodents pose threats to human and animal health, food security and infrastructure around the world, and humanity has spent centuries trying to mitigate the problems associated with these pests.

Rodents are known to be reservoir hosts for at least 60 zoonotic diseases and the potential transmission of these diseases creates a global risk to public health and safety, as well as agriculture, affecting crops, livestock, stored grain, and farm workers.

Diseases such as leptospirosis and salmonellosis directly impact reproductive efficiency in livestock, contaminate feed supplies, and increase liability exposure for agricultural operators.

Through consumption and contamination, rats destroy at least 20% of the global stored food supply every year.

Additionally, rats cause over $27 billion in damage to public and private infrastructure annually in the United States alone by burrowing beneath foundations and gnawing on electrical wiring, insulation, fire-proofing systems and equipment.

Over the centuries, the most prevalent response to rodent infestations has been an attempt to eliminate them through the use of lethal tools such as traps and rodenticides.

However, there are growing concerns about the environmental and ecological impact of rodenticides due to secondary exposure and bioaccumulation, including a push for safer and more humane products as consumer awareness increases.

While some of these challenges are of recent concern, the efficacy of how rodent infestations respond has always been limited by their extraordinary reproductive rate.

ContraPest, our initial product, is a liquid bait, containing the active ingredients 4-vinylcyclohexene diepoxide (“VCD”) and triptolide.

ContraPest targets the reproductive systems of both male and female rats, is a highly palatable formulation, does not cause illness or changed behavior in rats, and leads to significant reductions in fertility and rat populations.

Accordingly, ContraPest is an additional tool to use as part of an IPM program.

On August 2, 2016, the EPA granted an unconditional registration for ContraPest as a Restricted Use Product (“RUP”), requiring purchase or application oversight by a licensed professional.

On October 18, 2018, the EPA approved the removal of the RUP designation and ContraPest was reclassified as a general-use pesticide.

To date, ContraPest is registered in all 50 states (49 states and the District of Columbia have approved the RUP designation) and two major U.S.

territories, Puerto Rico and the U.S.

Virgin Islands.

On March 10, 2022, the EPA granted a sub-label for ContraPest allowing for an alternative delivery system in a hanging bait station.

This sub-label is marketed as Elevate Bait System™ and was designed to target roof rat habitats and infestations.

The Evolve product line, which began in the form of Evolve Rat, launched in January 2024, and is currently our lead product.

Compounding the problem, rats reproduce rapidly.

Even intensive lethal control efforts are often undermined by rapid population rebound, fueled by high fecundity, early sexual maturity, and density-dependent compensation.

Furthermore, urbanization, climate variability, and aging infrastructure are contributing to accelerated rodent population growth and heightened infestation pressures globally, including major metropolitan areas, thereby increasing associated economic costs and public health risks.

For centuries, the dominant response to rodent infestations has been eradication through lethal means—primarily traps and rodenticides.

Yet this approach is increasingly under scrutiny.

Mounting evidence of non-target secondary poisoning and bioaccumulation has heightened environmental and regulatory concerns, driving demand for ecologically-friendly alternatives as public awareness grows.

While ecological risks have come into sharper focus in recent years, a fundamental limitation of lethal management is rodents’ extraordinary reproductive capacity.

Traditional eradication strategies frequently provide only temporary suppression rather than long-term population control, perpetuating a costly cycle of reinfestation.

The Evolve product line launched in January 2024 as Evolve Rat and is currently our primary revenue-generating product.

Evolve Rat is a soft bait product that is novel to the pest control industry and contains the active ingredient cottonseed oil.

1 unchanged sentence

Additionally, its palatable formulation produces high acceptance for sustained consumption even when other sought-after food sources are present.

, Evolve Rat does not cause illness in rats and, therefore, it does not change behavior or result in bait aversion.

By targeting the

reproductive systems of both male and female rats, and with palatability promoting continued consumption, the use of Evolve can lead to sustained reductions of the rat population.

Evolve Rat meets the EPA’s minimum risk pesticide conditions under FIFRA, Section 25(b).

Due to its classification, Evolve is exempt from federal registration because it poses little to no risk to human health and the environment.

Evolve is also made from food ingredients with tolerance exemptions for both food and nonfood applications, which allows it to be used in agricultural application.

Evolve Rat does not cause acute adverse effects in rats and, therefore, it does not change behavior or result in bait aversion.

By targeting the reproductive systems of both male and female rats, and with palatability promoting continued consumption, the use of Evolve Rat can lead to a sustained reduction of the rat population.

Evolve Rat meets the EPA’s minimum risk pesticide conditions under Section 25(b) of FIFRA.

Due to its classification, Evolve Rat is exempt from federal registration because it poses little to no risk to human health and the environment.

Evolve Rat is also made from food ingredients with tolerance exemptions for both food and nonfood applications, which allows it to be used in agricultural applications.

There are 10 states that accept the federal exemption for pesticide registration and require no additional determination or approval.

In states that do not accept the federal exemption, we must obtain registration from the various state regulatory agencies.

To date, we are authorized to sell Evolve in 48 states.

In May 2024, we launched Evolve Mouse, our latest iteration of the Evolve product line.

Evolve Mouse is a modified version of our soft bait technology and contains the active ingredient, cottonseed oil.

Evolve Mouse limits reproduction of male and female mice and is also considered a minimum risk pesticide under the EPA’s FIFRA, Section 25(b).

To date, we are authorized to sell Evolve Mouse in 35 states.

We are continuously enhancing ContraPest and Evolve to align with the unique needs and environments of our customers in our target verticals while simultaneously pursuing regulatory approvals and amendments to our existing U.S.

As of the date hereof, we are authorized to sell Evolve Rat in 48 states and territories.

In May 2024, we introduced Evolve Mouse, expanding the Evolve product line to address additional rodent species.

Evolve Mouse is a modified version of our soft bait technology and contains the same active ingredient, cottonseed oil.

Evolve Mouse limits reproduction of male and female mice and is also considered a minimum risk pesticide under Section 25(b) of FIFRA.

As of the date hereof, we are authorized to sell Evolve Mouse in 37 states and territories.

We have also begun to market Evolve products internationally through distributors.

ContraPest, our initial product, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide (“VCD”) and triptolide.

Accordingly, ContraPest is an additional tool to use as part of an IPM program.

In August 2016, the EPA granted an unconditional registration for ContraPest as a Restricted Use Product (“RUP”), requiring purchase or application oversight by a licensed professional.

In October 2018, the EPA approved the removal of the RUP designation and ContraPest was reclassified as a general-use pesticide.

As of the date hereof, ContraPest is registered in all 50 states, the District of Columbia, and two major U.S.

territories, Puerto Rico and the U.S.

Virgin Islands, all of which have approved the removal of the RUP designation except the State of Connecticut.

In March 2022, the EPA granted a sub-label for ContraPest allowing for an alternative delivery system in a hanging dispenser.

This sub-label is marketed as Elevate Bait System™ and was designed to target roof rat habitats and hard to reach areas where traditional bait stations are impractical.

We are continuously enhancing Evolve and ContraPest to align with the unique needs and environments of our customers in our target verticals while simultaneously pursuing regulatory approvals and amendments to our existing U.S.

registration to broaden its use and marketability.

When regulatory and financial conditions permit, we will seek regulatory approval for additional jurisdictions beyond the United States.

When regulatory and financial conditions permit, we plan to continue to seek regulatory approval for additional jurisdictions beyond the United States.

Current Challenges in Pest Control Methodologies

Under ideal conditions, a female rat can yield up to 15,000 descendants in approximately 12 months.

Lethal control measures such as traps and rodenticides are often at the forefront of rat control programs.

However, this reproduction rate, along with intelligence and genetic resistance to the active ingredients in rodenticides, can negatively impact results of traditional mitigation efforts.

Under optimal conditions, theoretical models suggest that a single breeding pair of rats could produce up to 15,000 descendants in approximately 12 months.

Rodents reach sexual maturity between approximately six to nine weeks of age.

2 unchanged sentences

This prolific breeding can cause populations to rebound quickly even after implementing a lethal control program.

Traditional lethal control methods and fertility control approaches operate through fundamentally different mechanisms and may present different risk profiles, timelines, and regulatory considerations.

The relative effectiveness of any approach depends on environmental conditions, population dynamics, and implementation practices.

Lethal control measure such as traps and rodenticides are often at the forefront of rat control programs.

Published ecological research indicates that lethal population control measure may be followed by compensatory reproductive responses.

These responses can include earlier sexual maturity, increased litter sizes, higher breeding frequency, and recolonization from surrounding areas.

This phenomenon, often described as density-dependent reproduction, has been documented in wildlife and population ecology literature.

The extent to which such efforts occur can vary based on species, environmental conditions, and management practices.

Rodent behavior, either learned or innate, can negatively affect pest control efforts.

Neophobia, or the fear and avoidance of new objects, is an innate behavior that often impacts control efforts.

Rats avoid bait stations, loose bait, or traps until they are confident that these new objects pose no danger.

2 unchanged sentences

Resistance to traditional rodenticides creates challenges for rodent control programs.

Rodents, like all animals, are hard-wired to survive.

Further, some rats can be born with a genetic mutation making them resistant to certain rodenticides.

Studies show that resistance is increasing in commensal rodents as resistance can be passed onto offspring who will then carry this resistant trait into future generations.

Some rats can be born with a genetic mutation making them resistant to certain rodenticides due to prolonged use of anticoagulants in rodent management.

Multiple published studies have documented increasing resistance in certain rodent populations to both first-generation and second-generation anticoagulant rodenticides.

Such resistance can reduce product efficacy and, in some cases, may contribute to prolonged control efforts, increased risk of secondary exposure to non-target species, and heightened regulatory scrutiny.

Fertility control products operate through a non-lethal mechanism of action and therefore are not subject to anticoagulant resistance dynamics.

Studies show that resistance is increasing in commensal rodents as the gene can be passed onto offspring who will then carry this resistant trait into future generations.

Because of these factors, traditional rodenticide producers are continually challenged to develop new, more lethal chemicals to control future rat populations.

5 unchanged sentences

The American Society for the Prevention of Cruelty to Animals (“ASPCA”) reports that these substances are highly toxic to cats and dogs leading to severe health issues such as internal bleeding, kidney failure, seizures, or even death.

Studies show that anticoagulant rodenticides are the most reported substance causing pet poisonings.

The American Association of Poison Control Centers reported the number of human cases between

2011 and 2015 was a cumulative total of 44,095 and 1,029 for long-acting superwarfarin-type and warfarin-type drugs, respectively, and 88% of these involved children under the age of five.

Studies show that anticoagulant rodenticides are the most reported substance causing pet poisoning.

America’s Poison Centers’ 2024 annual report of the National Poison Data System (“NPDS”) lists a total of 2,999 human cases involving long-acting and warfarin-type anticoagulant rodenticides and 97% of these incidents included children under the age of five.

In addition to direct exposure to humans, chemicals in rodenticides have also been found as contaminates in the food supply.

In November 2022, the EPA announced an update to its Endangered Species Act of 1973 (“ESA”) Workplan to expand the protection efforts for endangered species potentially affected by rodenticides.

In November 2024, the EPA released its final Biological Evaluations for 11 rodenticide active ingredients, assessing their potential effects on approximately 90 endangered species and their critical habitats.

These evaluations guide regulatory actions and implement mitigation measures to restrict or condition rodenticide use in areas where endangered species may be present to reduce exposure risks.

Such measures include specifying distances between rodenticide application sites and critical habitat to create buffer zones, restricting application by limiting how and where rodenticides can be applied, and requiring training and certification for applicators that ensures safe and targeted use.

In addition, they require rodenticide label updates to reflect new usage restrictions, mitigation measures and environmental protection guidelines, which can alter market preference to shift toward more attractive, non-lethal solutions.

Changes to the EPA’s review and registration policies could affect filings with the agency due to expanded test requirements for mammals, birds, reptiles, and critical habitats.

ContraPest is not a traditional rodenticide and does not contain the active ingredients under this evaluation.

While these requirements (or a subset) do not directly impact our registration, ContraPest is classified in the rodenticide category with the EPA, therefore, updates to ContraPest’s current registration or newly registered products with the agency in the future may be subject to stricter testing requirements or limitations on use.

However, ContraPest, under its current registration, and the exemption status of Evolve as a 25b pesticide, offers a distinct competitive advantage in the rodent control market through its alternative non-lethal and environmentally benign products.

Integrated Pest Management and Fertility Control

The most effective, long-term way to manage rodents is by using a combination of tools that work together to magnify the efficacy of the pest management protocol;

The most effective, long-term way to manage rodents is to use a combination of tools that work together to magnify the efficacy of the pest management protocol;

IPM is based upon this concept.

The EPA defines IPM as an effective and environmentally sensitive approach to pest management that relies on a combination of common-sense practices through use of current, comprehensive information on the life cycles of pests and their interaction with the environment.

The EPA defines IPM as an effective and environmentally sensitive approach to pest management that relies on a combination of common-sense practices and current, comprehensive information on the life cycles of pests and their interaction with the environment.

This approach considers the least hazardous and most economical option to people, property, and the environment.

An effective IPM program should reduce the existing rat population, while preventing recurrence of the problem thus limiting continual application of hazardous chemicals such as lethal rodenticides.

Based on company field research, the addition of a fertility control product to an IPM program has demonstrated improved efficacy of more than 90% with sustained population suppression.

Based on company field research, the addition of a fertility control product to an IPM program has demonstrated more than 90% efficacy, with sustained population suppression.

A fertility control program reduces the reproduction and therefore the risk of future population spikes, known in the industry as the rebound effect.

1 unchanged sentence

This happens because it becomes harder for individuals to find mates and to reproduce.

As a result, the population declines even faster, helping suppress or even eliminate it.

Accordingly, fertility control can reduce the reliance on poisons or their frequency of use, allowing for a pest control program that focus on maintenance only.

Updates to the EPA’s ESA Workplan in November 2024 strongly encourage a shift towards IPM that promotes alternatives to rodenticides, including non-lethal and environmentally safer solutions.

This shift aligns with our fertility control products, ContraPest and Evolve.

The EPA has indicated a willingness to collaborate with manufacturers and stakeholders to ensure compliance and explore safer alternatives given the recent ESA changes.

As the first and only EPA registered liquid contraceptive bait for use on Norway rat and roof rat populations, ContraPest was – and remains – a novel product among a catalog of lethal rodenticides that have dominated the market.

The EPA granted us waivers for several studies typically required for new rodenticide products at the time ContraPest was initially registered because of its low risk profile and use characteristics.

While there may be limitations to how and where ContraPest can be used, ContraPest’s product features align with the agency’s agenda to provide alternative IPM solutions and allows us the potential opportunity to further expand our partnerships.

As a result, the population declines even faster, helping to suppress or even eliminate it.

Accordingly, fertility control can reduce reliance on poisons or their frequency of use, allowing for a pest control program that focuses on maintenance only.

Updates to the EPA’s ESA Workplan issued in November 2024 emphasize a shift towards IPM strategies that promotes alternatives to traditional rodenticides, including non-lethal and ecologically-friendly solutions.

This policy shift aligns with our fertility control products, ContraPest and Evolve.

The EPA has indicated a willingness to collaborate with manufacturers and stakeholders to ensure compliance with recent ESA changes and to advance ecologically-friendly alternatives.

As the first and only EPA registered liquid contraceptive bait for use on male and female Norway rats and roof rats, ContraPest was – and remains – a novel alternative in a market dominated by lethal rodenticides.

At the time of ContraPest’s initial registration, the EPA granted waivers for several studies typically required for rodenticides, reflecting ContraPest’s low risk profile and use characteristics.

While label restrictions may limit certain applications, ContraPest’s features align with the EPA’s IPM objectives and create opportunities to expand partnerships and adoption of non-lethal rodent control solutions.

company studies)

Regulatory Outlook

In November 2022, the EPA announced an update to its ESA Workplan to expand the protection efforts for endangered species potentially affected by rodenticides.

These evaluations guide regulatory actions and the implementation of mitigation measures to restrict or condition

rodenticide use in areas where endangered species may be present to reduce exposure risks.

In addition, they require rodenticide label updates to reflect new usage restrictions, mitigation measures, and environmental protection guidelines, which can alter market preference to shift toward more attractive, non-lethal solutions.

Changes to the EPA’s review and registration policies could affect filings with the EPA due to expanded test requirements for mammals, birds, reptiles, and critical habitats.

ContraPest is not a traditional rodenticide and does not contain the active ingredients under this evaluation.

However, ContraPest, under its current registration, and the exemption status of Evolve as a minimum risk pesticide under Section 25(b) of FIFRA, offers a distinct competitive advantage in the rodent control market through its alternative non-lethal and environmentally benign products.

Other Applications

While our proprietary technology is effective on rat species, our technology can be applied to other mammalian species.

We have explored and continue to evaluate fertility control in mice, feral dogs, and other species.

This preliminary data indicates potential for the continued development of fertility control technology in general.

We believe that the size of the rat control market is sufficient for our near-term focus.

We remain open to potentially to licensing our technology for our strategic partners to explore its applicability to other mammalian species.

While our proprietary technology is predominantly effective on rats, it may be applied to mice and other mammalian species.

We have explored and continue to evaluate the market potential for fertility control in other species, as well as other population management products.

We believe that the size of the rat control market is sufficient for our near-term focus and remain open to potentially licensing our technology to our strategic partners to explore its applicability in other mammalian species.

Business Strategy

Our goal is for fertility control to be a standard tool utilized in pest management in IPM programs across all verticals.

We will achieve this through the following:

We expect to achieve this through the following:

End User Awareness and Adoption.

Our focus is educating end users on the rapid reproduction rate of rodents, which draws attention to the complex issue of gaining control of an infestation when you do not have control of fertility.

As more rodenticides come to market to address rat populations, attention will be drawn to the impact other rodenticides may have on other species due to bioaccumulation, and the benefit of ContraPest and Evolve having a low potential for bioaccumulation.

We seek to educate end users regarding the rapid reproduction capacity of rodents and the challenges associated with managing infestations without addressing fertility.

As additional rodenticide products come to market and regulatory and environmental considerations, including bioaccumulation in non-target species remain areas of growing concern, the benefit of ContraPest and Evolve become increasingly advantageous in rodent mitigation strategies.

Our fertility control products align with the EPA’s recent push for non-lethal alternatives and reduced environmental impact.

Tailored Value Propositions.

While the general desire to achieve and maintain control of rat populations is universal among end users, each vertical has a specific pain point which may be improved through the use of fertility control.

While the general desire to achieve and maintain control of rat populations is universal among end users, each vertical has a specific pain point that may be improved through the use of fertility control.

By working with our existing customers and conducting field research, we are understanding and leveraging unique opportunities in our sales strategies across verticals.

1 unchanged sentence

• Product Development.

The needs of customers in each vertical vary due to environment and limitations, requiring ongoing innovation, exploration of additional species and the pursuit of additional regulatory approvals for ContraPest and Evolve, both in the United States and globally.

The needs of customers in each vertical vary due to environment and limitations, requiring ongoing innovation, exploration of additional products, and the pursuit of additional regulatory approvals for ContraPest and Evolve, both in the United States and globally.

• Strategic Partnerships.

Alignment with industry leaders and organizations accelerate awareness, adoption, product innovation and development.

Alignment with industry leaders and organizations accelerates awareness, adoption, product innovation and development.

• Efficiencies.

Through securing more reliable, affordable suppliers for our raw materials, and continuous development of our manufacturing process, we will be able to increase profits while scaling production to meet rising product demand and the production of additional registered products.

Through securing more reliable, affordable suppliers for our raw materials and continuous development of our manufacturing process, we expect to be able to increase profits while scaling production to meet rising product demand and the production of additional registered products.

Marketing and Sales Approach

ContraPest and Evolve are differentiated in what is otherwise a very crowded pest control market.

They are the only products registered with or exempt from registration by the EPA that restrict fertility in both male and female rats and are designed to be non-lethal.

As first and second generation anti-coagulant rodenticides come under increased scrutiny for non-target exposure and bioaccumulation impacts on non-target species as they travel up the food chain, their use is being restricted or banned in select areas across the United States and globally.

These increasing restrictions and bans create an opportunity to highlight the safety and efficacy of our products as industry professionals look for alternative tools to serve their customers and gain control of rat and mouse populations through nontraditional means.

Because the pest industry in the United States has demonstrated a reluctance to adopt new technologies, the marketing of fertility control has primarily been aimed at end-user and professional awareness, and penetration of the key verticals of agribusiness distribution, pest management distribution, industrial distribution, retail distribution, international distribution and e-commerce.

While pain points and benefits are unique to each vertical, they have shared core value propositions.

ContraPest and Evolve are differentiated in what is otherwise a very crowded pest control market due to their non-lethal design and innovative approach that focuses on the biology of the pest.

As first and second-generation anti-coagulant rodenticides come under increased scrutiny for non-target exposure and bioaccumulation impacts as they travel up the food chain, their use is being restricted or banned in select areas across the United States and globally.

These increasing

restrictions and bans create an opportunity to highlight the safety and efficacy of our products as industry professionals seek alternatives tools to serve their customers and gain control of rat and mouse populations through nontraditional means.

Because the pest industry in the United States has demonstrated a reluctance to adopt new technologies, the marketing of fertility control has primarily focused on building awareness among end users and professionals, while driving penetration across key distribution channels, including agribusiness, pest management, industrial, retail, international, and e-commerce markets.

Although each vertical presents distinct pain points and benefits, they share core value propositions.

• Fertility control is effective.

Lab tests and field research demonstrate more than 90% reduction in rat populations when added to an IPM with sustained population suppression;

• Our proprietary formulations and feeding systems optimize consumption and provides targeted delivery for maximum efficacy;

• ContraPest and Evolve are specifically designed to minimize exposure hazard for handlers and non-targeted species such as wildlife, livestock, and pets, with Evolve being designated by the EPA as a minimum risk product;

• Fertility control can be used as an anchor or enhancement for an IPM program, and as a solution to decrease reliance on poisons or other lethal control options.

Our lab and field research demonstrate more than 90% reduction in rat populations when added to an IPM with sustained population suppression;

• Our proprietary formulations and feeding systems optimize consumption and provide a targeted delivery for maximum efficacy;

• ContraPest and Evolve are specifically designed to minimize exposure hazard for handlers and non-targeted species such as wildlife, livestock, and pets, with Evolve meeting EPA requirements as a minimum risk product;

• Fertility control integrates seamlessly into the IPM framework by complimenting existing products and management strategies for more effective results, and offers a solution to decrease reliance on poisons.

We have also begun to market our Evolve products internationally through distributors.

Raw Materials and Manufacturing Process

The Evolve products contain one active ingredient, cottonseed oil, a plant-derived food product.

Evolve also contains several other inactive food ingredients.

The Evolve products contain one active ingredient, cottonseed oil, a plant-derived compound used in foods.

Evolve’s inactive ingredients also comprise common food ingredients or naturally derived compounds.

Currently, we source cottonseed oil from standard food suppliers, and it is available from a variety of sources.

Our manufacturing process for Evolve involves the incorporation of our active ingredient, in low concentration, into several inactive ingredients.

Once incorporated, the entire product is packaged inside of a casing and cut to length for sale.

This process allows Evolve to be delivered to rats and mice in a palatable, effective manner, and it is designed to be non-lethal.

ContraPest contains two active ingredients, VCD, an industrial chemical, and triptolide, a plant derived chemical.

ContraPest also contains several other inactive, generally recognized as safe, ingredients.

ContraPest contains two active ingredients, VCD, an industrial chemical, and triptolide, a plant-derived compound.

ContraPest also contains several inactive ingredients that are generally recognized as safe.

Currently, we source VCD from standard industrial chemical supply providers.

Triptolide is derived from the Thunder god vine, Tripterygium wilfordii, which is commonly cultivated and harvested wild in southeastern China and other Asian countries.

Triptolide is available from a variety of sources, but the process to purify triptolide for use in ContraPest is expensive.

Triptolide is derived from the Thunder god vine, Tripterygium wilfordii , which is commonly cultivated and harvested in southeastern China and other Asian countries.

Triptolide is available from a variety of sources, but the process for purifying it for use in ContraPest is expensive.

Thus, we are investigating other, less costly sources of triptolide.

Our manufacturing process involves the incorporation of our two active ingredients, in low concentrations, into several inactive ingredients.

Once incorporated, the entire product goes through a proprietary process in order to stabilize the final formulation.

This process allows ContraPest to be delivered to rats in a palatable, effective manner, and it is designed to be non-lethal.

Currently, we have production scale capability in our facilities in Arizona to manufacture ContraPest and Evolve.

Our internal production capabilities allow us to meet our current and anticipated demand through 2025 and beyond.

Scientific Background Regarding our Product

Our manufacturing process involves incorporating active ingredients into several inactive ingredients at low concentrations.

Once incorporated, the entire product undergoes a proprietary process in order to stabilize the final formulation.

This process allows our products to be delivered to the target species in a palatable, effective manner.

Currently, we have production-scale capability in our facility in Arizona to manufacture ContraPest and Evolve.

We believe that our internal production capabilities will allow us to meet our current and near term forecasted demand for our products.

Scientific Background Regarding our Products

Female rats are born with a finite number of eggs, or oocytes, and remain fertile until death.

4 unchanged sentences

The active ingredients in our products cause specific loss of small ovarian follicles (both primordial and primary) and growing follicles (secondary and antral).

In males, the active ingredients in our products exert a significant suppression of male fertility by preventing sperm maturation and impairing the movement of sperm.

In males, the active ingredients in our products exert a significant suppression of male fertility by impairing sperm maturation and mobility.

The safety and efficacy of our active ingredients and products are supported by considerable evidence.

The active ingredients are rapidly metabolized by the rat, limiting the possibility of bioaccumulation or effect on non-target species.

Further, based on laboratory and toxicology studies, ContraPest and Evolve should not cause rats to become ill or change their behavior.

Furthermore, ContraPest and Evolve are contraceptives, not sterilants, limiting fertility in male and female rats beginning with the first breeding cycle following consumption.

The average duration of infertility post consumption ranges from 42 to over 180 days.

Other Potential Products

We continue to explore the application of ContraPest and Evolve on other species.

We expect to continuously evaluate and evolve our current product offerings and, technology and market conditions permitting, introduce additional products.

Currently, we are unaware of any other non-lethal fertility control products targeting rats that are registered by the EPA.

The active ingredients are provided at low concentrations and require repeated exposure to produce infertility in the target species, thus limiting the possibility of bioaccumulation or effect on non-target species.

Further, based on laboratory and toxicology studies, ContraPest and Evolve have not been shown to cause illness in the target species.

Additionally, ContraPest and Evolve are contraceptives, not sterilants, limiting fertility in male and female rats beginning with the first breeding cycle following consumption.

The average duration of infertility post consumption ranges from two to four months.

Currently, we are unaware of any other non-lethal fertility control products targeting rats that are registered with the EPA.

There are non-registered products being sold online that claim to control rodent reproduction.

1 unchanged sentence

Our principal competition is large corporations with greater resources that offer a wider range of products.

Generally, these are lethal pest control products largely consisting of rodenticide-based products and other tools that Pest Management Provider (“PMPs”) use in their IPM.

Generally, these are lethal pest control products, largely consisting of rodenticide-based products and other tools that Pest Management Providers (“PMPs”) use in their IPM.

Government Regulation and Product Approval

Federal, state and local government authorities in the United States regulate, among other things, the testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, distribution, and marketing of the products we develop.

The process for obtaining regulatory approval and compliance with appropriate federal, state and local regulations is rigorous and requires the expenditure of substantial time and financial resources.

The process for obtaining regulatory approval and compliance with appropriate federal, state, and local regulations is rigorous and requires substantial time and financial resources.

United States Review and Approval Processes

In the United States, the EPA regulates the sale, distribution, and use of any pesticide under FIFRA.

The EPA’s definition of a pesticide includes “any substance or mixture of substances intended for preventing, destroying, repelling, or mitigating any pest.” FIFRA defines a pest as “any insect, rodent, nematode, fungus, or weed.” To register a new product with the EPA, all active ingredients within the product must be registered with the EPA or meet specific exemptions.

The EPA has an exemption under FIFRA, Section 25(b) which exempts certain pesticides from federal registration based on six criteria for minimum risk.

Evolve is exempt from registration as a minimum risk pesticide under FIFRA, Section 25(b).

All applicable requirements for registration, manufacturing, selling, or distributing into designated sates and territories have been met.

Evolve has not been registered by the EPA but is in the process of registering in all 50 states, the District of Columbia, and five major U.S.

The EPA has an exemption under Section 25(b) of FIFRA, which omits certain pesticides from federal registration based on six minimum risk criteria.

Evolve meets these criteria and is exempt from federal EPA registration under Section 25(b) designation as a minimum risk pesticide.

All applicable state-level requirements for registration, manufacturing, selling, or distributing of Evolve have been met.

There are 10 states that accept the federal exemption for pesticide registration within the respective state.

For the states that do not accept the federal exemption, we began the registration process for pesticide registration in October 2023.

To date, we are authorized to sell Evolve in 48 states.

The EPA granted registration for ContraPest effective August 2, 2016, and as of July 12, 2018, we have received registration for ContraPest in all 50 states, the District of Columbia, and five major U.S.

For the states that do not accept the federal exemption, we began the registration process for Evolve in October 2023.

As of the date hereof, we are authorized to sell Evolve Rat in 48 states and territories and Evolve Mouse in 37 states and territories.

As part of registration maintenance, any marketing label revisions, including claims, must be submitted and approved by states prior to their use in the marketplace as products under Section 25(b) of FIFRA.

The EPA granted registration for ContraPest effective August 2016, and as of July 2018, we had received registration for ContraPest in all 50 states, the District of Columbia, and two major U.S.

This initial EPA approval labeled ContraPest as a restricted-use product, due to the need for applicator expertise for deployment.

On October 18, 2018, the EPA removed the Restricted Use designation, meaning that we can sell ContraPest to consumers

who do not have applicator expertise.

In October 2018, the EPA removed the RUP designation, meaning that we can sell ContraPest to consumers who do not have applicator expertise.

ContraPest is currently limited by EPA requirements to indoor use and to use within one foot of manmade structures.

In addition to the EPA registration of ContraPest in the United States, we must obtain registration from the various state regulatory agencies prior to selling in each state.

To date, we have received registration for ContraPest in all 50 states and the District of Columbia, 49 of which have approved the removal of the Restricted Use designation.

In addition to product registration, the EPA also approves all labeling (the container label, instructional inserts, and the Safety Data Sheet) of ContraPest.

As of the date hereof, we have received registration for ContraPest in all 50 states and the District of Columbia, 49 of which have approved the removal of the RUP designation.

In addition to product registration of ContraPest, the EPA also approves all labeling (the container label, instructional inserts, and the Safety Data Sheet) and product claims.

Generally, states accept the EPA approved label as is.

ContraPest’s labeling was submitted to states at initial registration and is resubmitted during state scheduled reregistration or for any significant labeling change requiring EPA approval.

ContraPest’s labeling was submitted to states at initial registration and is resubmitted during state scheduled registration renewals or for any significant labeling change requiring EPA approval.

In certain cases, our EPA and state registrations require completion of testing and certifications even after we have received approval for the product or its labeling.

1 unchanged sentence

International Review and Approval Processes

With the assistance of in-country distributors, we are pursuing potential international markets and evaluating the regulatory landscapes of each prospective market.

Country-specific regulatory laws have provisions that include requirements for certain labeling, safety, efficacy and manufacturers’ quality control procedures to assure the consistency of the product, as well as company records and reports.

Some specific in-country studies will be required for particular countries, but others will generally accept an EPA or EU compliant dossier.

As of December 31, 2024, we had 23 full-time employees and no part-time employees.

With the assistance of in-country distributors, we are pursuing potential international markets and evaluating the regulatory landscapes of each prospective opportunity.

Country-specific regulatory laws have provisions that include requirements for labeling, testing and efficacy, and quality control procedures to assure the safety and consistency of the product, as well as

company records and reports for compliance purposes.

Specific in-country studies are required for some registration approvals while others generally accept an EPA or European Union compliant dossier.

As of December 31, 2025, we had 23 full-time employees and one part-time employee.

Within our workforce, 11 employees are engaged in manufacturing, quality assurance, and research and development, and 12 employees are engaged in sales, business development, finance, regulatory, human resources, facilities, information technology, and general management and administration.

1 unchanged sentence

Intellectual Property and Other Proprietary Rights

Maintaining a strong position in the rodenticide market requires constant innovation along with a healthy research program to evolve product lines in order to remain competitive and relevant to the needs of the changing global marketplace.

Maintaining a strong position in the rodenticide market requires constant innovation and a healthy research program to advance product lines in order to remain competitive and relevant to the needs of the changing global marketplace.

We seek to protect our proprietary data and trade secrets with attention to data exchanges among employees, consultants, collaborators and research and trade partners.

Patent Filings

Our intellectual property portfolio supporting ContraPest consists of nine international patent filings (in the United States, Europe, Canada, Brazil, Russia, Japan, Mexico, South Korea and Australia) addressing the ContraPest compound.

Claims directed toward the compound include composition-of-matter involving a diterpenoid epoxide or salts thereof in combination with an organic diepoxide, use claims for inducing follicle depletion and for reducing the reproductive capability of a mammalian animal or non-human mammalian population.

Issued claims will have a patent term extending to 2033 or longer based on patent term determinations in each of the filing countries.

The novelty of ContraPest extends to its method of field distribution and has required innovation to perfect the dosing of our product to rodents.

We have filed U.S.

and international patent applications covering our novel bait station device to effectively and efficiently deliver our rodent bait at individual bait sites that would, if issued, offer patent term protection through at least 2036.

Minimum risk pesticides regulated under FIFRA Section 25(b) are required to disclose product ingredient composition on the label as a condition of exemption from federal registration.

Accordingly, to help maintain our competitive position as the manufacturer of fertility control products for pest management of commensal rodents, we filed a U.S.

utility patent application for Evolve that covers its composition and formulation for use as a rodent contraceptive.

The application includes claims directed to bait and soft-bait formulations comprising low-dose gossypol and a carrier containing a bulk feed component, which may be enclosed in a casing such as collagen, for use in mice, rats, and other members of the order Rodentia.

If issued, the patent would provide protection through 2044.

While issuance would not guarantee complete protection, we believe the claims – particularly those directed to efficacious, non-toxic dosage ranges tailored to the body mass of small rodents to reduce fertility – would provide meaningful intellectual property protection.

Our intellectual property portfolio supporting ContraPest includes U.S.

patent filings covering the ContraPest compound.

Claims directed toward the compound include composition-of-matter involving a diterpenoid epoxide comprising a triptolide skeleton in combination with an organic diepoxide which causes ovarian follicle depletion for reducing the reproductive capacity of non-human mammalian populations.

Issued claims will have a patent term extending to 2033.

The novelty of ContraPest extends to its methods of application and has required innovation to perfect the efficient delivery and effective dosing of our product to rodents at individual bait sites.

We have a patent for our unique tank and tray delivery system with term protection through 2038 and have filed U.S.

and international patent applications covering our novel Elevate bait station that would, if issued, offer patent term protection through at least 2043.

Trade Secrets and Trademarks

1 unchanged sentence

We protect these proprietary assets with a combination of confidentiality terms in all commercial agreements or stand-alone confidentiality agreements along with rights-ownership agreements and structured information transfer understandings prior to beginning any collaborative projects.

We own and maintain the ContraPest trademark and have initiated registration for Evolve.

We intend to register new trademarks for products from our evolving rodenticide product line and for products for mammalian species beyond rodentia.

We own and maintain the ContraPest and Evolve trademarks, as well as Rat Birth Control, and have initiated registration for both Mouse and Rodent Birth Control.

We intend to register new trademarks for products in our evolving product line, and products for mammalian species beyond rodentia.

We have exclusive-use status with the EPA for the data-sets we have developed and submitted to the EPA as part of our application for ContraPest.

1 unchanged sentence

For five years after the 10-year period of exclusivity, if another applicant or the EPA Administrator chooses to rely on one or more data sets that we submitted in support of an application submitted by another applicant, the new applicant must make a binding offer to compensate us and certify to the EPA that it has done so.

If we and the offeror cannot reach agreement on the terms of the compensation for the use of such data sets, FIFRA requires resolution by binding arbitration.

The EPA rules do not describe how the compensation should be determined, and there is publicly available information about some, but not all, binding arbitration decisions.

If the offeror cannot reach an agreement on the terms of the compensation for the use of such data sets, FIFRA requires resolution by binding arbitration.

The EPA rules do not specify how the compensation should be determined, and there is publicly available information about some, but not all, binding arbitration decisions.

Our 10-year exclusivity period with

the EPA is set to expire on August 2, 2026, and we are exploring potential pathways and qualifying factors for an extension by substantiated claims.

Incorporation and Capital Structure

We were originally incorporated in the State of Nevada in July 2004, and on November 12, 2015, we reincorporated in the State of Delaware.

Our corporate headquarters and manufacturing site are in Phoenix, Arizona.

On December 8, 2016, we went public and are currently traded on the Nasdaq under the symbol SNES.

We were originally incorporated in the State of Nevada in July 2004, and in November 2015, we reincorporated in the State of Delaware.

Our corporate headquarters and manufacturing site are in Surprise, Arizona.

In December 2016, we went public and are currently traded on Nasdaq under the symbol SNES.

In July 2024, we amended our Amended and Restated Certificate of Incorporation to effect a 1-for-10 reverse split of our issued and outstanding shares of common stock.

1 unchanged sentence

All issued and outstanding common stock, options, and warrants exercisable for common stock, restricted stock units, and per share amounts contained in our financial statements have been retrospectively adjusted.

Where You Can Find Additional Information

We electronically file with the SEC our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act.

We make available on our website at www.senestech.com, free of charge, copies of these reports, as soon as reasonably practicable after electronically filing such reports with, or furnishing them to, the SEC.

The information contained in, or that can be accessed through, our website is not part of, and is not incorporated into, this Annual Report on Form 10-K.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business